Vincent D'Andrea

ORCID: 0000-0001-9343-8092
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Prostate Cancer Diagnosis and Treatment
  • Prostate Cancer Treatment and Research
  • Advanced Radiotherapy Techniques
  • Epigenetics and DNA Methylation
  • Cancer, Hypoxia, and Metabolism
  • Renal cell carcinoma treatment
  • Testicular diseases and treatments
  • Chromatin Remodeling and Cancer
  • DNA Repair Mechanisms
  • Consumer Retail Behavior Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Mechanisms and Therapy
  • Cancer, Lipids, and Metabolism
  • Urinary and Genital Oncology Studies
  • Global Cancer Incidence and Screening
  • Venous Thromboembolism Diagnosis and Management
  • Body Image and Dysmorphia Studies
  • Diversity and Career in Medicine
  • Anatomy and Medical Technology
  • Surgical Simulation and Training
  • Parathyroid Disorders and Treatments
  • Medical Imaging and Pathology Studies
  • Smoking Behavior and Cessation
  • Fibroblast Growth Factor Research

Brigham and Women's Hospital
2023-2025

Dana-Farber Brigham Cancer Center
2024

Harvard University
2023-2024

Dana-Farber Cancer Institute
2023-2024

Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
2020

Northwell Health
2020

North Shore Diabetes and Endocrine Associates
2019

Stanford University
1987-2019

Hofstra University
2019

Università Cattolica del Sacro Cuore
2010

Article AbstractBackground: Compulsive shopping, a DSM-IV impulse-control disorder not otherwise specified, is characterized by preoccupation with shopping and inability to resist buying unneeded items, resulting marked distress, social or occupational impairment, financial and/or familial problems. Because an open-label trial suggested that fluvoxamine, selective serotonin reuptake inhibitor (SSRI), effective for this disorder, we tested the effectiveness of SSRI citalopram. Method: We...

10.4088/jcp.v63n0808 article EN The Journal of Clinical Psychiatry 2002-08-15

Younger patients with bladder cancer typically have fewer environmental exposures or risk factors, suggesting molecular pathways implicated in early-onset disease differ from older patients. Dissecting the genomic profile of tumors may define targeted treatments for these young We compared frequency somatic mutations cancer, defined as diagnosis before age 55 years old which encompasses about 1 10 diagnoses, two cohorts: Mass General Brigham Young Cystectomy Cohort (MGB-YCC, n=134 patients)...

10.1101/2025.01.10.25320337 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2025-01-12

Abstract Antibody-drug conjugates (ADCs) are transforming the treatment landscape in metastatic bladder cancer, but role of ADCs localized disease is uncertain. Radiation a central component trimodality therapy (TMT), curative-intent approach for muscle-invasive cancer (MIBC) that includes concurrent radiation and cytotoxic chemotherapy. We investigated safety efficacy combining novel with preclinical models. observed additive cytotoxicity vitro, combination conformal fractionated was...

10.1158/1557-3265.targetedtherap-a011 article EN Clinical Cancer Research 2025-01-26

Purpose: Retroperitoneal lymph node dissection (RPLND) is an essential component of multimodal treatment testicular cancer. The latest data on the perioperative outcomes RPLNDs performed using open approach (O-RPLND) dates back over a decade. We report our contemporary institutional with O-RPLND. Materials and Methods: retrospectively identified all patients who underwent O-RPLND between 2013 2022 across institution. Clinical demographic were reviewed recorded. Descriptive statistics...

10.1097/ju9.0000000000000114 article EN cc-by-nc-nd JU Open Plus 2024-02-29

664 Background: Antibody-drug conjugates (ADCs) are a novel class of therapeutics that combine tumor cell targeting antibody with cytotoxic payload. Two ADCs currently approved in the US for treatment advanced bladder cancer: enfortumab vedotin (EV) and sacituzumab govitecan (SG). Radiation therapy (RT) plays central role trimodality (TMT), curative approach muscle-invasive cancer (MIBC). However, biological activity combined RT preclinical MIBC models has not been reported. Methods: We use...

10.1200/jco.2024.42.4_suppl.664 article EN Journal of Clinical Oncology 2024-01-29

SWI/SNF (BAF) complexes are a diverse family of ATP-dependent chromatin remodelers produced by combinatorial assembly that mutated in and thought to contribute 20% human cancers large number neurologic diseases. The gene-activating functions BAF essential for viability many cell types, limiting the development small molecule inhibitors. To circumvent potential toxicity inhibition, we identified molecules inhibit specific repressive function these but relatively non-toxic importantly...

10.1101/660456 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2019-06-04

656 Background: ARID1A is an essential component of the BAF complex, a large SWI/SNF chromatin-remodeling complex which implicated in bladder cancer (BC) pathogenesis. While mutations are more highly represented metastatic rather than localized tumors, biological consequences loss BC remain to be elucidated. We hypothesize that deficiency primes invasive transformation BC, thus increasing likelihood disease progression and metastases. used CRISPR/Cas9-mediated gene editing knockout (KO)...

10.1200/jco.2024.42.4_suppl.656 article EN Journal of Clinical Oncology 2024-01-29

665 Background: Approximately 10% of urothelial cancer (UC) patients have defects in the NER pathway and at least another HRR pathway. Tumors with or are more sensitive to platinum-based chemotherapy due inability repair platinum-induced DNA damage. Two ADCs, sacituzumab govitecan (SG) enfortumab vedotin (EV) approved for treatment metastatic UC. The cytotoxic payload attached SG EV SN-38 MMAE respectively. directly damages through inhibition Topoisomerase 1 activity during replication...

10.1200/jco.2024.42.4_suppl.665 article EN Journal of Clinical Oncology 2024-01-29

672 Background: Large-scale genomic studies of bladder cancer (BC) have identified MAPK as a recurrent pathway alteration. The is signaling cascade comprising the proteins RAF, MEK, and ERK, which together control critical cellular processes. Currently, cisplatin-based chemotherapy anti-PD1/PD-L1 agents are backbone systemic therapy in BC, yet only subset patients respond. As such, additional novel therapeutic strategies, such targeting pathway, needed. Herein, we describe impact alterations...

10.1200/jco.2024.42.4_suppl.672 article EN Journal of Clinical Oncology 2024-01-29

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology III (MP65)1 May 2024MP65-11 ARID1A LOSS IN BLADDER CANCER CORRELATES WITH GENETIC SIGNATURES OF CELL MIGRATION DYSREGULATION Vincent D'Andrea, Christopher Magnani, Timothy Hanlon, Rea Chroneos, Clinton, Filipe L. F. Carvalho, and Kent Mouw D'AndreaVincent D'Andrea , MagnaniChristopher Magnani HanlonTimothy Hanlon ChroneosRea Chroneos ClintonTimothy Clinton CarvalhoFilipe Carvalho MouwKent View All Author...

10.1097/01.ju.0001008756.24343.22.11 article EN The Journal of Urology 2024-04-15
Coming Soon ...